IntrinsicIntrinsic
← All summaries

Absci Corp

ABSI
Financials & Chart →

Business Summary

Absci Corporation (ABSI) is a clinical-stage biopharmaceutical company that employs an AI-native approach to develop differentiated antibody therapeutics. The company's core business model leverages its "Integrated Drug Creation platform," which combines a generative design model called Origin-1 with rapid validation through a "lab-in-the-loop" system. This platform is designed to accelerate drug discovery and preclinical development, aiming to reduce the typical industry timeline of 4-6 years and cost of over $50 million per product candidate to approximately two years with a total investment of around $15 million per program . Absci generates revenue primarily through fees from drug creation agreements with partners, which include upfront payments, project-based milestones, and potential future clinical, regulatory, and commercial milestones, as well as royalties on net product sales . The company focuses on underexplored biological mechanisms where unmet medical need is high and competition is low, aiming to establish first-in-class or best-in-class positions .

Absci's Integrated Drug Creation platform is central to its strategy, facilitating the design of antibody-based therapeutics against difficult-to-drug targets. The platform's "lab-in-a-loop" approach involves generating high-quality data at scale in wet labs for AI model training and testing, using technologies such as high-throughput Surface Plasmon Resonance (SPR) and the ACE assay . Generative AI models, including Origin-1, create epitope-specific product candidates in silico, while AI lead optimization models enable multi-parametric optimization of attributes like binding affinity, immunogenicity, pharmacological profile, and developability . The wet lab then validates these AI-designed candidates, with the continuous feedback loop refining data and strengthening the models . Origin-1, released in January 2026, is designed for de novo design of full-length monoclonal antibodies against "zero-prior" epitopes, which are target sites without published reports of a known protein binder . It has been validated against four targets, showing binding, developability, and ~100nM functional potency, with experimental structures matching design models closely .

The company's pipeline includes internally developed programs and partnered programs. Internally developed programs are designed to address significant unmet medical needs, with Absci intending to advance a limited number, such as ABS-201, through clinical development and potential commercialization . For other internally generated programs, Absci may seek collaboration, partnership, or out-licensing arrangements at various stages . Partnered programs involve drug creation collaborations with third parties, which may include upfront fees, research fees, and potential clinical/commercial milestones and royalties . Absci has a track record of partnerships with biopharmaceutical companies including Merck, AstraZeneca, and Almirall .

Absci is currently advancing five wholly-owned, internally developed programs, along with several undisclosed early discovery programs . Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody with an extended half-life, being developed for androgenetic alopecia (AGA) and endometriosis . ABS-201 is in a Phase 1/2a clinical trial (HEADLINE™ NCT07317544) for AGA, a condition affecting approximately 80 million people in the United States . The first three single ascending dose cohorts have been dosed with a favorable safety profile, and interim proof-of-concept data are expected in the second half of 2026 . For endometriosis, a chronic condition affecting about 10% of women of reproductive age worldwide, a Phase 2 clinical trial for ABS-201 is planned for the fourth quarter of 2026, subject to data from the HEADLINE trial and regulatory considerations . ABS-101, a program for Inflammatory Bowel Disease (IBD), initiated a Phase 1 clinical trial in May 2025 and showed positive interim Phase 1 results in November 2025, but Absci has strategically decided to seek a partner for its later-stage development to prioritize ABS-201 . Preclinical stage programs include ABS-301, an oncology asset discovered via reverse immunology, and ABS-501, a HER2 program .

For the fiscal year ended December 31, 2025, Absci reported total partner program revenue of $2.8 million , a decrease from $4.5 million in the prior year . The company incurred a net loss of $115.2 million , compared to a net loss of $103.1 million in 2024 . Research and development expenses increased by $17.6 million , or 27% , to $81.4 million from $63.9 million in 2024 . Selling, general, and administrative expenses decreased by $1.1 million , or 3% , to $35.1 million from $36.2 million in 2024 . Depreciation and amortization expense decreased by $1.6 million , or 12% , to $11.7 million from $13.4 million in 2024 . The company recognized a $5.1 million gain on the settlement of contingent consideration related to the Totient acquisition . Operating loss was $120.3 million , compared to $108.9 million in 2024 . Interest expense decreased by $0.4 million , or 63% , to $0.2 million from $0.6 million in 2024 . Other income, net, was $5.4 million , a decrease of $1.0 million , or 16% , from $6.4 million in 2024 . Basic and diluted net loss per share was $(0.84) for 2025, compared to $(0.94) for 2024. As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $144.3 million , and the accumulated deficit was $624.8 million . Net cash used in operating activities was $92.9 million in 2025, up from $72.4 million in 2024. Net cash used in investing activities was $50.2 million , and net cash provided by financing activities was $105.9 million .

Year-over-year, partner program revenue decreased by $1.7 million , or 38% , primarily due to the timing of project-based milestones and the mix of ongoing program activity . Research and development expenses increased by $17.6 million , or 27% , driven by $17.3 million from the advancement of drug creation programs, including $13.1 million in direct external preclinical and clinical development costs for ABS-101 and ABS-201, and a $1.9 million increase in personnel costs and stock-based compensation, partially offset by a $1.6 million decrease in other lab costs . Selling, general, and administrative expenses decreased by $1.1 million , or 3% , mainly due to a $1.5 million decrease in personnel and stock-based compensation costs . Depreciation and amortization decreased by $1.6 million , or 12% , primarily due to disposals of lab equipment . The company's net loss increased from $103.1 million in 2024 to $115.2 million in 2025.

During 2025, Absci initiated the HEADLINE™ Phase 1/2a clinical trial for ABS-201 in December , and dosed the first three single ascending dose cohorts . In May 2025, a Phase 1 clinical trial for ABS-101 in healthy volunteers was initiated, with positive interim results announced in November 2025, though the company decided to seek a partner for its later-stage development . In January 2025, Absci entered into a strategic collaboration with Advanced Micro Devices, Inc. (AMD) to optimize AMD Instinct™ accelerators and ROCm™ software for AI drug creation . As part of this collaboration, AMD invested $20.0 million through the purchase of 5,714,285 shares of Absci's common stock in a private investment in public equity (PIPE) at a premium over the market price . In October 2025, Absci settled a contingent consideration liability of $15.0 million related to the 2021 merger with Totient, Inc. for a payment of approximately $7.6 million , recognizing a $5.1 million gain . The remaining $8.7 million held as restricted cash was released from escrow to the company .

Business Outlook

Absci expects to continue incurring significant expenses in connection with its ongoing activities, including the development of ABS-201 and other internally developed programs through preclinical and clinical stages, continued discovery, research, and development efforts through existing and new partnerships, and investments in technology enhancements for its Integrated Drug Creation platform . The company also anticipates costs associated with attracting, retaining, and motivating highly qualified personnel .

A major growth area is the advancement of ABS-201. For androgenetic alopecia (AGA), interim proof-of-concept data, including exploratory efficacy endpoints, are expected in the second half of 2026 . The company plans to initiate three multiple ascending dose (MAD) cohorts in the second quarter of 2026, each enrolling approximately 49 healthy volunteers with AGA . Complete proof-of-concept data for AGA are anticipated in early 2027, with one-year safety follow-up data expected later in 2027 . For endometriosis, a Phase 2 clinical trial evaluating ABS-201 is planned for the fourth quarter of 2026, subject to data from the ongoing HEADLINE trial and regulatory considerations, with potential proof-of-concept data in the second half of 2027 . The company believes ABS-201 has the potential to provide durable, disease-modifying effects and establish a new treatment category for both indications .

Another growth vector involves leveraging the Integrated Drug Creation platform to expand its pipeline of internally developed programs beyond ABS-201. This includes advancing early-stage oncology and immunology and inflammation programs, such as ABS-301 (a potential first-in-class oncology asset discovered through reverse immunology) and ABS-501 (a potentially differentiated HER2 program) . Absci plans to provide more information about these additional programs selectively and to seek partnerships or out-licenses for select programs as they advance . The company's strategy is to generate internally developed programs that address underexplored biological mechanisms in areas of significant unmet medical need, with the potential for first-in-class or disease-modifying approaches .

Absci expects research and development expenses to increase in absolute dollars over the long term as it develops and advances internally developed programs through preclinical and clinical activities, enters into additional partnerships, and continues to invest in technology enhancements . Personnel-related costs for executive, business development, legal, finance, human resources, information technology, and other administrative functions are expected to increase in absolute dollars as the company expands its clinical development and regulatory operations and prepares for potential future commercial launches . The company also expects to actively manage other general and administrative expenses .

The company intends to maintain its technological differentiation through continuous investment in its team and platform, expecting to maintain an integrated team of subject matter experts in AI, drug discovery, disease biology, protein engineering, and clinical development . It also expects to grow and enhance its intellectual property portfolio to protect innovations and may evaluate strategic and synergistic technology acquisitions . Absci's long-term goals for its AI technology, such as constructing deep learning models capable of in silico target identification and drug and cell line design, continue to require significant investment and long development timelines .

Absci believes its current cash, cash equivalents, and marketable securities of $144.3 million as of December 31, 2025, and anticipated cash flows from operations will be sufficient to meet its working capital and capital expenditure needs over at least the next 12 months . However, future capital requirements will depend on factors such as the ability to raise additional capital through equity or debt financing, the progress of preclinical and clinical activities for internally developed programs, the success of new and existing partnerships, and the successful commercialization of approved product candidates . The company may consider raising additional capital in the future to expand its business, pursue strategic investments, take advantage of financing opportunities, or fund capital expenditures and general and administrative expenses .

The company's ability to use its U.S. federal and state net operating losses (NOLs) to offset future taxable income may be limited due to past or future "ownership changes" as defined under Sections 382 and 383 of the Internal Revenue Code . Changes in tax laws, such as the One Big Beautiful Bill Act of 2025 (OBBBA), which allows 100% expensing of domestic R&D expenses for tax years after December 31, 2024, and increases the business interest expense deduction limit, have been analyzed and reflected, with no material impact on the tax rate for 2025 . Certain international taxation provisions under OBBBA will take effect in future years, but are not anticipated to materially impact the effective income tax rate .

Risk Factors

Absci faces substantial risks, including the inherent uncertainty of biologic drug development, where positive early preclinical or preliminary clinical results may not predict later success, potentially leading to delays, increased costs, or termination of programs . The company relies heavily on third parties for preclinical studies and clinical trials, and their failure to perform as required, satisfy regulations, or meet deadlines could delay or derail internally developed programs . Supply chain disruptions, manufacturing problems, or limited cGMP manufacturing capacity could also cause delays in development, approval, or commercialization . The markets for both its Integrated Drug Creation platform and internally developed programs are highly competitive, with numerous pharmaceutical, biotechnology, and AI-based drug design companies, some with significantly greater resources, potentially leading to Absci's inability to compete effectively . The market may also be skeptical of the viability of Absci's novel synthetic biology and AI technologies, hindering partnership formation . Furthermore, the company's partnership strategy depends on partners successfully advancing and commercializing product candidates, over which Absci has little control, and failure to do so would limit milestone and royalty revenues . Operational risks include the potential for its single Vancouver facility to become damaged or inoperable, jeopardizing drug creation and R&D efforts . The evolving nature of AI technologies presents risks such as bias, hallucinations, misinformation, and cybersecurity threats, which could lead to reputational harm, legal liability, and increased compliance costs, especially with new regulations like the EU's AI Act and various U.S. state laws . Disruptions to government agencies like the FDA, due to funding shortages, shutdowns, or policy changes, could delay regulatory reviews and approvals . Changes in healthcare laws and regulations, including reform efforts aimed at lowering drug prices, could impact the commercial viability and profitability of any approved products . The company has incurred significant losses since inception, with an accumulated deficit of $624.8 million as of December 31, 2025, and will require additional capital to fund operations, preclinical and clinical development, and platform improvements, which may not be available on acceptable terms or could result in stockholder dilution . Intellectual property protection is critical but limited, with risks of challenges to patents, inability to protect trade secrets, and potential infringement claims from third parties, which could incur substantial costs and divert management attention .

Management Priorities

Management emphasizes Absci's AI-native approach and Integrated Drug Creation platform as central to its strategy, highlighting its ability to advance programs from AI design to IND in approximately two years with a total investment of around $15 million per program , significantly faster and more capital-efficient than the industry average of 4-6 years and over $50 million . The company is focused on executing on near-term catalysts while building long-term pipeline value, particularly through its lead product candidate, ABS-201, which is being evaluated in the HEADLINE™ Phase 1/2a clinical trial for androgenetic alopecia (AGA) and is planned for a Phase 2 clinical trial in endometriosis in the fourth quarter of 2026 . Management anticipates reporting preliminary safety, tolerability, and pharmacokinetic data for ABS-201 in the first half of 2026, with interim proof-of-concept data expected in the second half of 2026 . A key strategic priority is the continuous investment in its team and Integrated Drug Creation platform to maintain technological differentiation and expand capabilities, including generative AI deep learning technology and computational antibody and target discovery . Another priority is advancing a diverse portfolio of internally developed programs, leveraging the platform to create antibody-based therapeutics against complex and hard-to-drug targets, while also seeking partnerships or out-licensing arrangements for select programs to provide non-dilutive capital . Management also highlighted the strategic decision to seek a partner for ABS-101, despite positive interim Phase 1 results, to prioritize ABS-201 due to significant unmet medical needs and greater potential return on investment in AGA and endometriosis .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Overview
  2. [2] Item 7, MD&A — Revenue
  3. [3] Item 1, Business — Overview
  4. [4] Item 1, Business — Our Integrated Drug Creation Platform
  5. [5] Item 1, Business — AI to Create
  6. [6] Item 1, Business — Our Integrated Drug Creation Platform
  7. [7] Item 1, Business — Origin 1
  8. [8] Item 1, Business — Origin 1
  9. [9] Item 1, Business — Internally Developed Programs
  10. [10] Item 1, Business — Internally Developed Programs
  11. [11] Item 1, Business — Partnered Programs
  12. [12] Item 1, Business — Partnered Programs
  13. [13] Item 1, Business — Internally Developed Programs
  14. [14] Item 1, Business — Overview
  15. [15] Item 1, Business — Androgenetic Alopecia
  16. [16] Item 1, Business — Androgenetic Alopecia
  17. [17] Item 1, Business — Endometriosis
  18. [18] Item 1, Business — ABS-101
  19. [19] Item 1, Business — Preclinical Stage Programs
  20. [20] Item 7, MD&A — Financial results
  21. [21] Item 7, MD&A — Financial results
  22. [22] Item 7, MD&A — Financial results
  23. [23] Item 7, MD&A — Financial results
  24. [24] Item 7, MD&A — Financial results
  25. [25] Item 7, MD&A — Operating expenses
  26. [26] Item 7, MD&A — Operating expenses
  27. [27] Item 7, MD&A — Operating expenses
  28. [28] Item 7, MD&A — Operating expenses
  29. [29] Item 7, MD&A — Operating expenses
  30. [30] Item 7, MD&A — Operating expenses
  31. [31] Item 7, MD&A — Operating expenses
  32. [32] Item 7, MD&A — Operating expenses
  33. [33] Item 7, MD&A — Operating expenses
  34. [34] Item 7, MD&A — Operating expenses
  35. [35] Item 7, MD&A — Operating expenses
  36. [36] Item 7, MD&A — Gain on settlement of contingent consideration
  37. [37] Item 7, MD&A — Results of Operations
  38. [38] Item 7, MD&A — Results of Operations
  39. [39] Item 7, MD&A — Interest expense
  40. [40] Item 7, MD&A — Interest expense
  41. [41] Item 7, MD&A — Interest expense
  42. [42] Item 7, MD&A — Interest expense
  43. [43] Item 7, MD&A — Other income, net
  44. [44] Item 7, MD&A — Other income, net
  45. [45] Item 7, MD&A — Other income, net
  46. [46] Item 7, MD&A — Other income, net
  47. [47] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  48. [48] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  49. [49] Item 7, MD&A — Financial results
  50. [50] Item 7, MD&A — Financial results
  51. [51] Item 7, MD&A — Cash flows from operating activities
  52. [52] Item 7, MD&A — Cash flows from operating activities
  53. [53] Item 7, MD&A — Cash flows from investing activities
  54. [54] Item 7, MD&A — Cash flows from financing activities
  55. [55] Item 7, MD&A — Revenue
  56. [56] Item 7, MD&A — Revenue
  57. [57] Item 7, MD&A — Revenue
  58. [58] Item 7, MD&A — Research and development
  59. [59] Item 7, MD&A — Research and development
  60. [60] Item 7, MD&A — Research and development
  61. [61] Item 7, MD&A — Research and development
  62. [62] Item 7, MD&A — Research and development
  63. [63] Item 7, MD&A — Research and development
  64. [64] Item 7, MD&A — Research and development
  65. [65] Item 7, MD&A — Selling, general and administrative expenses
  66. [66] Item 7, MD&A — Selling, general and administrative expenses
  67. [67] Item 7, MD&A — Selling, general and administrative expenses
  68. [68] Item 7, MD&A — Selling, general and administrative expenses
  69. [69] Item 7, MD&A — Depreciation and amortization
  70. [70] Item 7, MD&A — Depreciation and amortization
  71. [71] Item 7, MD&A — Depreciation and amortization
  72. [72] Item 7, MD&A — Financial results
  73. [73] Item 7, MD&A — Financial results
  74. [74] Item 1, Business — Clinical Stage Programs
  75. [75] Item 1, Business — Clinical Trials
  76. [76] Item 1, Business — ABS-101
  77. [77] Item 7, MD&A — AMD strategic collaboration
  78. [78] Item 7, MD&A — AMD strategic collaboration
  79. [79] Item 7, MD&A — AMD strategic collaboration
  80. [80] Item 7, MD&A — AMD strategic collaboration
  81. [81] Item 7, MD&A — Gain on settlement of contingent consideration
  82. [82] Item 7, MD&A — Gain on settlement of contingent consideration
  83. [83] Item 7, MD&A — Gain on settlement of contingent consideration
  84. [84] Item 7, MD&A — Gain on settlement of contingent consideration
  85. [85] Item 7, MD&A — Gain on settlement of contingent consideration
  86. [86] Item 7, MD&A — Overview
  87. [87] Item 7, MD&A — Overview
  88. [88] Item 1, Business — Androgenetic Alopecia
  89. [89] Item 1, Business — Clinical Trials
  90. [90] Item 1, Business — Clinical Trials
  91. [91] Item 1, Business — Endometriosis
  92. [92] Item 1, Business — Overview
  93. [93] Item 1, Business — Preclinical Stage Programs
  94. [94] Item 1, Business — Preclinical Stage Programs
  95. [95] Item 1, Business — Strategy
  96. [96] Item 7, MD&A — Research and development
  97. [97] Item 7, MD&A — Selling, general, and administrative
  98. [98] Item 7, MD&A — Selling, general, and administrative
  99. [99] Item 1, Business — Continuous investment in our team and integrated drug creation platform
  100. [100] Item 1, Business — Continuous investment in our team and integrated drug creation platform
  101. [101] Item 1A, Risk Factors — We expect to make significant investments in our continued research and development of new technology, which may not be successful.
  102. [102] Item 7, MD&A — Liquidity and Capital Resources Overview
  103. [103] Item 7, MD&A — Liquidity and Capital Resources Overview
  104. [104] Item 7, MD&A — Liquidity and Capital Resources Overview
  105. [105] Item 1A, Risk Factors — We will need to raise additional capital to fund our operations, pre-clinical and clinical development of our internally developed programs, and to improve our Integrated Drug Creation platform.
  106. [106] Item 1A, Risk Factors — Our ability to use our net operating losses and certain other tax attributes may be limited.
  107. [107] Item 1A, Risk Factors — Changes in tax law may adversely affect us or our investors.
  108. [108] Item 1A, Risk Factors — Changes in tax law may adversely affect us or our investors.
  109. [109] Item 1A, Risk Factors — Positive results from early preclinical studies or preliminary results from clinical trials of our product candidates are not necessarily predictive of the results of later preclinical studies and any future clinical trials of our product candidates.
  110. [110] Item 1A, Risk Factors — We rely and expect to continue to rely on third parties to conduct our preclinical studies and clinical trials.
  111. [111] Item 1A, Risk Factors — We could experience clinical supply and manufacturing problems that result in delays in the development, approval or commercialization of our product candidates or otherwise harm our business.
  112. [112] Item 1A, Risk Factors — The markets in which we operate, including those for Integrated Drug Creation platform technology and our Internally Developed Programs, are highly competitive, and if we are unable to compete effectively, our business and prospects could be adversely affected.
  113. [113] Item 1A, Risk Factors — The market for our platform, including potential partners and potential investors, may be skeptical of the viability and benefits of our Integrated Drug Creation platform because it is based on novel and complex synthetic biology and AI technologies.
  114. [114] Item 1A, Risk Factors — Our partnership strategy significantly depends on the eventual approval and commercialization of product candidates developed under our partnerships for which we may have no control over the clinical development plan, regulatory strategy or commercialization efforts.
  115. [115] Item 1A, Risk Factors — If our operating facility becomes damaged or inoperable or we are required to vacate our facility, our ability to conduct and pursue our drug creation and internal research and development efforts may be jeopardized.
  116. [116] Item 1A, Risk Factors — Our current and future use of evolving technologies, such as artificial intelligence (AI), may present risks and challenges that can impact our business, including by posing cybersecurity and other risks to our confidential and/or proprietary information, including personal information, and as a result we may be exposed to operational challenges, reputational harm and potential liability.
  117. [117] Item 1A, Risk Factors — Disruptions to the operations of the FDA, the SEC or other government agencies, including due to funding shortages, government shutdowns, policy changes or staffing reductions, could delay regulatory reviews, approvals or other governmental actions on which our business depends, which could adversely affect our business.
  118. [118] Item 1A, Risk Factors — Healthcare reform efforts aimed at lowering the price of biopharmaceutical products may impact our ability to maintain sufficient profits.
  119. [119] Item 7, MD&A — Financial results
  120. [120] Item 1A, Risk Factors — We will need to raise additional capital to fund our operations, pre-clinical and clinical development of our internally developed programs, and to improve our Integrated Drug Creation platform.
  121. [121] Item 1A, Risk Factors — If we are unable to obtain and maintain sufficient intellectual property protection for our technologies and product candidates, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or product candidates similar or identical to ours, and our ability to successfully leverage our technologies or product candidates may be impaired.
  122. [122] Item 7, MD&A — Overview
  123. [123] Item 7, MD&A — Overview
  124. [124] Item 7, MD&A — Overview
  125. [125] Item 1, Business — Clinical Trials
  126. [126] Item 1, Business — Strategy
  127. [127] Item 1, Business — Strategy
  128. [128] Item 1, Business — ABS-101

Analysis on 5/19/2026